Fused tricyclic mGIuR1 antagonists as therapeutic agents
    5.
    发明申请
    Fused tricyclic mGIuR1 antagonists as therapeutic agents 失效
    融合的三环mGIuR1拮抗剂作为治疗剂

    公开(公告)号:US20070072864A1

    公开(公告)日:2007-03-29

    申请号:US11505140

    申请日:2006-08-16

    IPC分类号: C07D487/22 A61K31/503

    CPC分类号: C07D487/22 C07D495/14

    摘要: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

    摘要翻译: 在其许多实施方案中,本发明提供了式I的三环化合物(其中J 1,X 3,X 3,Z和R 1) ,R 3和R 4如本文所定义),其用作代谢型谷氨酸受体(mGluR)拮抗剂,特别是作为选择性代谢型谷氨酸受体1拮抗剂,含有化合物的药物组合物 以及使用化合物和组合物治疗与代谢型谷氨酸受体(例如,mGluR1)相关的疾病例如疼痛,偏头痛,焦虑症,尿失禁和神经变性疾病如阿尔茨海默病的治疗方法。

    Fused tricyclic mGluR1 antagonists as therapeutic agents
    6.
    发明申请
    Fused tricyclic mGluR1 antagonists as therapeutic agents 失效
    融合的三环mGluR1拮抗剂作为治疗剂

    公开(公告)号:US20070072863A1

    公开(公告)日:2007-03-29

    申请号:US11504860

    申请日:2006-08-16

    摘要: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

    摘要翻译: 在其许多实施方案中,本发明提供式I的三环化合物(其中J 1,X 3,X,Z和R 1) 可用作代谢型谷氨酸受体(mGluR)拮抗剂,特别是作为选择性代谢型谷氨酸受体1拮抗剂的药物组合物,以及使用该化合物和组合物的治疗方法 治疗与代谢型谷氨酸受体(例如,mGluR1)相关的疾病,例如疼痛,偏头痛,焦虑症,尿失禁和神经变性疾病如阿尔茨海默氏病。